CD200 and neoplasm: The human CD200R-9aas-CD28cys receptor also worked efficiently to augment CD8+ T cell proliferation and function on activation by CD200-expressing human tumor cells in phase 2 clinical trial (NCT01640301,table 1).39 Oda et al developed another receptor composed of the Fas ectodomain/transmembrane and 4-1BB intracellular tail, Fastm-4-1BB, which can convert a death signal to a prosurvival signal to T cells and enhances T cell therapy for cancer.40